These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38020763)

  • 1. The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis.
    Li J; Wu X; Tan X; Wang S; Qu R; Wu X; Chen Z; Wang Z; Chen G
    Front Aging Neurosci; 2023; 15():1257973. PubMed ID: 38020763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Qiao Y; Gu J; Yu M; Chi Y; Ma Y
    CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer's disease trials.
    Abanto J; Dwivedi AK; Imbimbo BP; Espay AJ
    Brain; 2024 Oct; 147(10):3513-3521. PubMed ID: 39259179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
    Wang XC; Chu CL; Li HC; Lu K; Liu CJ; Cai YF; Quan SJ; Zhang SJ
    Front Neurol; 2022; 13():1018027. PubMed ID: 36530613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
    Jeremic D; Navarro-López JD; Jiménez-Díaz L
    Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of three kinds of anti-amyloid-β drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: A systematic review and meta-analysis of phase II/III clinical trials in Alzheimer's disease.
    Lyu D; Lyu X; Huang L; Fang B
    Ageing Res Rev; 2023 Jul; 88():101959. PubMed ID: 37217078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer's Disease Patients: A Systematic Review and Meta-Analysis.
    Penninkilampi R; Brothers HM; Eslick GD
    J Alzheimers Dis; 2016 Jul; 53(4):1395-404. PubMed ID: 27392862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
    Qiao Y; Chi Y; Zhang Q; Ma Y
    Front Aging Neurosci; 2023; 15():1169499. PubMed ID: 37213538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal clinically important difference in Alzheimer's disease: Rapid review.
    Muir RT; Hill MD; Black SE; Smith EE
    Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of monoclonal antibodies against amyloid-beta
    Hao Y; Dong M; Sun Y; Duan X; Niu W
    Front Neurol; 2023; 14():1147757. PubMed ID: 37006475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rTMS treatment on global cognitive function in Alzheimer's disease: A systematic review and meta-analysis.
    Zhang T; Sui Y; Lu Q; Xu X; Zhu Y; Dai W; Shen Y; Wang T
    Front Aging Neurosci; 2022; 14():984708. PubMed ID: 36158564
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Zhang Y; Tian J; Ni J; Wei M; Li T; Shi J
    Front Pharmacol; 2023; 14():1268000. PubMed ID: 38283842
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial.
    Xuan K; Zhao T; Qu G; Liu H; Chen X; Sun Y
    Neurol Sci; 2020 Jun; 41(6):1391-1404. PubMed ID: 31930449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
    Lu L; Zheng X; Wang S; Tang C; Zhang Y; Yao G; Zeng J; Ge S; Wen H; Xu M; Guyatt G; Xu N
    J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1316-1324. PubMed ID: 33046560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.
    Dantas JM; Mutarelli A; Navalha DDP; Dagostin CS; Romeiro PHCL; Felix N; Nogueira A; Batista S; Teixeira L; Caramelli P
    Neurol Sci; 2024 Jun; 45(6):2461-2469. PubMed ID: 37978096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.